Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. is grouped at the issuer level across 1 linked ticker lifecycle, combining public listing, delisting, source, and shareholder outcome records from the archive.
Lifecycle Map
Issuer enters the archive
Mar 6, 2020Lyra Therapeutics, Inc. is represented as an issuer-level entity with 1 linked public-market ticker lifecycle.
Delisting event
Apr 20, 2026Removed from listing - SEC Form 25 filed.
SourceLYRA stopped trading
Apr 20, 2026LYRA is linked to Lyra Therapeutics, Inc. and ended with final status "delisted".
Source
Entity Graph
Lyra Therapeutics, Inc.issuedLYRA
LYRAlisted onNASDAQ
LYRAresulted inunknown
Source-Backed Claims
- On April 13, 2026, Lyra Therapeutics, Inc. entered into a Termination of Sublease with RVAC Medicines (US), Inc.8-K
- The sublease for approximately 23,704 rentable square feet at 880 Winter Street, Waltham, Massachusetts was originally dated December 21, 2023.8-K
- The sublease terminated effective March 31, 2026, with the Company required to surrender the premises no later than May 31, 2026.8-K
- As consideration for the termination, Lyra Therapeutics agreed to pay a termination payment of $2,100,000.00.8-K
- Upon completion of surrender obligations and receipt of the termination payment, RVAC will return Lyra Therapeutics' $600,501.32 letter of credit security deposit.8-K
- Lyra Therapeutics' rent obligations under the sublease terminated as of January 31, 2026.8-K
Associated Tickers
Public-market security lifecycles tied to this issuer record.